Resources

The Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation committed to the advancement of cell and gene therapies has released its Good Manufacturing Practice (GMP) Report 2024.

Degree apprentice with AstraZeneca, Emily Butterworth, becomes the first Manchester Met apprentice to be highly commended in the Royal Society of Biology’s Apprentice of the Year Awards 2024.

Facility dedicated to cryopreservation of leukapheresis starting materials to support clinical and commercial cell-based therapy programs

AUCATZYL is the first CAR T therapy approved by the FDA with no requirement for a REMS program (Risk Evaluation Mitigation Strategy); Approval based on FELIX clinical trial of obe-cel in adult patients with r/r B-ALL

Rinri Therapeutics, which is focused on transforming hearing loss treatment with regenerative cell therapy, announces that the novel surgical procedure to be used for regenerative cell delivery in its first-in-human trial has been published in the prestigious journal Nature Scientific Reports.

Ikarovec’s seed round extension raises funds to continue advanced pre-clinical trials of novel gene therapies to treat blindness and major chronic eye disease.

This is part of a series of blogs focussing on hearing therapeutics from different sector perspectives. In this blog, Karen Steel shares her thoughts on what she perceives to be some of the biggest opportunities in relation to the development of new treatments for hearing loss.

eXmoor and Virica receive funding to improve AAV gene therapy manufacturing. Partners will develop formulations of VSEs™ and validate their ability to improve yields of adeno-associated vector (AAVs) at scale, lowering gene therapy costs at commercial scale. Virica and eXmoor will receive advisory services and funding through collaborative Canada-UK government program.

Cellular Origins and Fresenius Kabi, an operating company of Fresenius, announce today they have signed a development agreement that leverages each company’s expertise in cell and gene therapies.

Enara Bio announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors.

Laverock Therapeutics announced significant progress in the industrialisation and validation of its technology platform enabling broadening of its potential therapeutic application.

The Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in the advancement of the cell and gene therapy industry, has appointed a new Non-Executive Director to its board, Dr Hsin Loke. 

Quell Therapeutics expands manufacturing capabilities for CAR-Treg cell therapy pipeline through partnership with eXmoor pharma. The multi-year agreement focuses on the manufacture of multiple CAR-Treg product candidates for Phase 1/2 clinical studies.

LinkGevity, an AI-driven drug discovery company focused on longevity and age-related disease, announces its selection for the highly competitive SPACE-H Accelerator program, powered by Starburst in collaboration with NASA’s Human Research Program (NASA HRP), the Translational Research Institute for Space Health (TRISH), and Microsoft Federal (Microsoft).

CGT Catapult has revealed new data highlighting the UK’s potential to become a global leader in the sector. Its 2024 annual review demonstrates how, with coherent and concerted action, the UK can take the lead in harnessing the potential of these therapies to deliver life-changing benefits to patients and economic growth to the nation.

In a ground-breaking collaboration, leading biotechnology companies and research organizations in the UK and Canada are entering into an R&D project jointly funded by a £1.1 million grant from Innovate UK (part of UK Research and Innovation) and the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP).

eXmoor’s Cell & Gene Therapy Centre can now offer a full range of GMP services for cell and gene therapies including manufacture, fill/finish, packaging, labelling, and shipping to global clinical sites

Connect with Fellow Leaders Shaping Cell and Gene Therapy Development

Boehringer Ingelheim has joined forces with digital health firm Brainomix on a project to improve the care of people with fibrosing lung diseases in the US.